ArticleCancer research communications2023

A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer.

Esteban Terzo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.